Management of noninfectious diarrhea associated with HIV and highly active antiretroviral therapy

Research output: Contribution to journalReview article

5 Citations (Scopus)

Abstract

In geographic locations where highly active antiretroviral therapy (HAART) is widely available, the nature of HIV-related diarrhea has shifted from being predominantly a consequence of opportunistic infection to being largely a side effect of HAART agents. With this shift has come a smaller risk for the life-threatening wasting and weight loss, although serious instances of noninfectious diarrhea remain a concern. While estimates vary, in part due to the lack of a standard diarrhea definition, over a quarter of patients receiving HAART experience diarrhea. The negative effect on quality-of-life in patients with HAART-related diarrhea is profound; diarrhea may also increase the risk of poor adherence to treatment, with potentially serious effects on viral suppression and increased risk of drug resistance. Diagnosis of HAART-related diarrhea largely involves ruling out pathogen involvement, which, in addition to laboratory testing, may require endoscopic examination. Treatment was, until recently, mainly supportive in nature. The recent US Food and Drug Administration approval of crofelemer offers the first reliably effective treatment for HAART-related diarrhea.

Original languageEnglish (US)
Pages (from-to)s238-45
Number of pages8
JournalAmerican Journal of Managed Care
Volume19
Issue number12 SUPPL.
StatePublished - Sep 2013

Fingerprint

Highly Active Antiretroviral Therapy
Diarrhea
HIV
Anti-Retroviral Agents
Drug Approval
Geographic Locations
Opportunistic Infections
Drug Resistance
Weight Loss
Therapeutics
Quality of Life
Food

ASJC Scopus subject areas

  • Health Policy
  • Medicine(all)

Cite this

Management of noninfectious diarrhea associated with HIV and highly active antiretroviral therapy. / MacArthur, Rodger D.

In: American Journal of Managed Care, Vol. 19, No. 12 SUPPL., 09.2013, p. s238-45.

Research output: Contribution to journalReview article

@article{f6a2f1dde0f2493d8151e1e6b9284da8,
title = "Management of noninfectious diarrhea associated with HIV and highly active antiretroviral therapy",
abstract = "In geographic locations where highly active antiretroviral therapy (HAART) is widely available, the nature of HIV-related diarrhea has shifted from being predominantly a consequence of opportunistic infection to being largely a side effect of HAART agents. With this shift has come a smaller risk for the life-threatening wasting and weight loss, although serious instances of noninfectious diarrhea remain a concern. While estimates vary, in part due to the lack of a standard diarrhea definition, over a quarter of patients receiving HAART experience diarrhea. The negative effect on quality-of-life in patients with HAART-related diarrhea is profound; diarrhea may also increase the risk of poor adherence to treatment, with potentially serious effects on viral suppression and increased risk of drug resistance. Diagnosis of HAART-related diarrhea largely involves ruling out pathogen involvement, which, in addition to laboratory testing, may require endoscopic examination. Treatment was, until recently, mainly supportive in nature. The recent US Food and Drug Administration approval of crofelemer offers the first reliably effective treatment for HAART-related diarrhea.",
author = "MacArthur, {Rodger D.}",
year = "2013",
month = "9",
language = "English (US)",
volume = "19",
pages = "s238--45",
journal = "The American journal of managed care",
issn = "1088-0224",
publisher = "Ascend Media",
number = "12 SUPPL.",

}

TY - JOUR

T1 - Management of noninfectious diarrhea associated with HIV and highly active antiretroviral therapy

AU - MacArthur, Rodger D.

PY - 2013/9

Y1 - 2013/9

N2 - In geographic locations where highly active antiretroviral therapy (HAART) is widely available, the nature of HIV-related diarrhea has shifted from being predominantly a consequence of opportunistic infection to being largely a side effect of HAART agents. With this shift has come a smaller risk for the life-threatening wasting and weight loss, although serious instances of noninfectious diarrhea remain a concern. While estimates vary, in part due to the lack of a standard diarrhea definition, over a quarter of patients receiving HAART experience diarrhea. The negative effect on quality-of-life in patients with HAART-related diarrhea is profound; diarrhea may also increase the risk of poor adherence to treatment, with potentially serious effects on viral suppression and increased risk of drug resistance. Diagnosis of HAART-related diarrhea largely involves ruling out pathogen involvement, which, in addition to laboratory testing, may require endoscopic examination. Treatment was, until recently, mainly supportive in nature. The recent US Food and Drug Administration approval of crofelemer offers the first reliably effective treatment for HAART-related diarrhea.

AB - In geographic locations where highly active antiretroviral therapy (HAART) is widely available, the nature of HIV-related diarrhea has shifted from being predominantly a consequence of opportunistic infection to being largely a side effect of HAART agents. With this shift has come a smaller risk for the life-threatening wasting and weight loss, although serious instances of noninfectious diarrhea remain a concern. While estimates vary, in part due to the lack of a standard diarrhea definition, over a quarter of patients receiving HAART experience diarrhea. The negative effect on quality-of-life in patients with HAART-related diarrhea is profound; diarrhea may also increase the risk of poor adherence to treatment, with potentially serious effects on viral suppression and increased risk of drug resistance. Diagnosis of HAART-related diarrhea largely involves ruling out pathogen involvement, which, in addition to laboratory testing, may require endoscopic examination. Treatment was, until recently, mainly supportive in nature. The recent US Food and Drug Administration approval of crofelemer offers the first reliably effective treatment for HAART-related diarrhea.

UR - http://www.scopus.com/inward/record.url?scp=84905259462&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84905259462&partnerID=8YFLogxK

M3 - Review article

C2 - 24495294

AN - SCOPUS:84905259462

VL - 19

SP - s238-45

JO - The American journal of managed care

JF - The American journal of managed care

SN - 1088-0224

IS - 12 SUPPL.

ER -